Fab’entech Launches H5N1 Phase I Trial In Singapore

Fab'entech Launches H5N1 Phase I Trial In Singapore

Pharma
October 15, 2012

French biotech Fab’entech has launched a Phase I clinical trial in Singapore for its product against the H5N1 Avian Influenza virus.

AsianScientist (Oct. 15, 2012) – French biotech Fab’entech, which specializes in developing specific polyclonal immunoglobulins against emerging infectious diseases, has launched a Phase I clinical trial in Singapore for its product against the H5N1 Avian Influenza virus.

This approach is based on passive immunotherapy which consists in injecting patients with specific antibodies (immunoglobulins) capable of recognizing, targeting and neutralizing the virus.

“The Phase 1 clinical trial represents an important milestone in providing a potential innovative solution to combat H5N1 virus infections in humans,” said founder and CEO of Fab’entech, Dr. Bertrand Lepine, MD.

“The clinical trial will take place in Singapore, located in the Asia-Pacific region where the risk of propagation of H5N1 virus is one of the highest in the world. The injection of specific anti-H5N1 polyclonal immunoglobulins is likely to provide immediate protection for people who have been infected with or exposed to the virus.”

According to Fab’entech, the good safety profile and the efficacy of this product have been extensively documented in animal studies conducted in collaboration with the INSERM Jean Merieux BSL-4 Laboratory in Lyon, France.

The clinical trial in Singapore will involve 16 healthy adult volunteers who will be monitored for five weeks. It will be a double blinded, placebo controlled study, performed in strict compliance with Good Clinical Practices (GCP).

Avian influenza is an infectious disease caused by the A(H5N1) strain of the influenza virus, which occurs primarily in birds.

Historically, human infections with avian influenza viruses have been extremely rare but certain H5N1 strains can cause serious infections in humans with a mortality rate that can reach 60 to 80 percent in some regions, particularly in Asia.

According to World Health Organization (WHO), 608 human cases have been reported since 2003, including 30 human cases in the first half of 2012. The scientific community estimates that an H5N1 influenza pandemic remains a real threat, particularly if the H5N1 virus were to mutate and become transmissible between humans.

——

Source: Fab’entech.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

« « BACK
NEXT » »